Xi Venture Capital supports international innovative enterprise Ruiyue Biotechnology for targeted protein degradation

　　Recently, Xi Venture Capital participated in the C-round financing of Ruiyue Biotechnology, a leading enterprise in targeted protein degradation technology platform. This is also the first investment since the restructuring of the company's biopharmaceutical team. This will help Ruiyue Biotechnology accelerate the development of more potential targeted protein degradation drug product lines, thereby bringing new treatment methods to patients who are fighting cancer.

　　Ruiyue Biotechnology is committed to developing innovative new chemical entities to treat diseases for which there are currently no effective treatment methods. Based on the latest progress in protein degradation technology, it is developing a unique proprietary technology platform - ubiquitin mediated small molecule induced target elimination technology, which has a leading position in this field and is highly competitive internationally. Based on over 20 years of research and key discoveries on the ubiquitin enzyme system, the founder of Ruiyue Biotechnology has demonstrated that this underlying technology can rapidly generate a large number of highly effective, selective, and biologically available compounds, while the entire process is more cost-effective compared to traditional drug discovery methods. Ruiyue Biotechnology is currently making rapid progress as the world's first broad-spectrum anti-cancer TRK protein degrading agent, which has been approved by the China National Medical Products Administration for clinical research on the treatment of advanced solid tumors.